From: Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial
 | Placebo |  | Vitamin D |  | P-value |
---|---|---|---|---|---|
(n = 25) | (n = 25) | ||||
Antropometric data: | |||||
 Age (years) | 69±6 |  | 67±8 |  | 0.464 |
 Gender (male/female) | 19/6 |  | 19/6 |  | 1.000 |
 BMI (kg/m2) | 24±6 |  | 25±5 |  | 0.587 |
 GOLD Stages |  |  |  |  | 0.492 |
 I (n) | 0 |  | 2 |  |  |
 II (n) | 6 |  | 7 |  |  |
 III (n) | 15 |  | 12 |  |  |
 IV (n) | 4 |  | 4 |  |  |
Serum vitamin D level: | Â | Â | Â | Â | Â |
 25-OHD (ng/ml) | 20±11 |  | 23±15 |  | 0.492 |
Pulmonary function: | |||||
 FEV1(l) | 1.06±0.28 | 40±10(*) | 1.22±0.50 | 47±18(*) | 0.115 |
 FVC (l) | 2.85±0.80 | 83±20(*) | 2.96±0.76 | 89±22(*) | 0.328 |
Muscle function: | Â | Â | Â | Â | Â |
 QF (Nm) | 106±36 | 83±27(*) | 109±41 | 75±20(*) | 0.242 |
 MIP (cmH2O) | −77±26 | 72±20(*) | −67±24 | 63±21(*) | 0.107 |
 MEP (cmH2O) | 158±55 | 83±22(*) | 152±50 | 80±26(*) | 0.685 |
Exercise Performance: | Â | Â | Â | Â | Â |
 6MWD (meter) | 422±109 | 70±19(*) | 391±135 | 65±23(*) | 0.435 |
 VO2max (l/min) | 1.21±0.48 | 72±24(*) | 1.15±0.43 | 75±38(*) | 0.802 |
 Wmax (watt) | 71±27 | 54±22(*) | 67±29 | 52±25(*) | 0.713 |
Health-Related Quality of Life: | |||||
 CRDQdyspnea (points) | 16.1±4.36 |  | 17.3±4.6 |  | 0.366 |
 CRDQtotal (points) | 82.6±16.0 |  | 83.1±17.4 |  | 0.721 |